Targeting the PD-1/PD-L1 axis in the treatment of lung cancer

[1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.SiegelRLMillerKDJemalA.Cancer statistics, 2015CA Cancer J Clin20156552910.3322/caac.21254Search in Google Scholar

[2]Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694-705.GroomePABolejackVCrowleyJJKennedyCKrasnikMSobinLHet alThe IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumoursJ Thorac Oncol20072869470510.1097/JTO.0b013e31812d05d5Search in Google Scholar

[3]Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46.RosellRCarcerenyEGervaisRVergnenegreAMassutiBFelipet alErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol20121332394610.1016/S1470-2045(11)70393-XSearch in Google Scholar

[4]Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-51.YangJCWuYLSchulerMSebastianMPopatSYamamotoNet alAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol20151621415110.1016/S1470-2045(14)71173-8Search in Google Scholar

[5]Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57.MokTSWuYLThongprasertSYangCHChuDTSaijoNet alGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med2009361109475710.1056/NEJMoa081069919692680Search in Google Scholar

[6]Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-77.SolomonBJMokTKimDWWuYLNakagawaKMekhailTet alFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med20143712321677710.1056/NEJMoa140844025470694Search in Google Scholar

[7]Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963-71.ShawATOuSHBangYJCamidgeDRSolomonBJSalgiaRet alCrizotinib in ROS1-rearranged non-small-cell lung cancerN Engl J Med20143712119637110.1056/NEJMoa1406766426452725264305Search in Google Scholar

[8]Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE et al. Phase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530-5.LaraPNJrNataleRCrowleyJLenzHJRedmanMWCarletonJEet alPhase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124J Clin Oncol200927152530510.1200/JCO.2008.20.1061268485519349543Search in Google Scholar

[9]Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005;23(16):3752-9.NiellHBHerndonJE2ndMillerAAWatsonDMSandlerABKellyKet alRandomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732J Clin Oncol200523163752910.1200/JCO.2005.09.07115923572Search in Google Scholar

[10]Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol. 2002;20(19):3947-55.ArdizzoniATjan-HeijnenVCPostmusPEBuchholzEBiesmaBKarnicka-MlodkowskaHet alStandard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923J Clin Oncol2002201939475510.1200/JCO.2002.02.06912351591Search in Google Scholar

[11]Blank C, Mackensen A. Contribution of the PD-L1/ PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739-45.BlankCMackensenA.Contribution of the PD-L1/ PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasionCancer Immunol Immunother20075657394510.1007/s00262-006-0272-1Search in Google Scholar

[12]Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20.WolchokJDHoosAO’DaySWeberJSHamidOLebbéCet alGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res2009152374122010.1158/1078-0432.CCR-09-1624Search in Google Scholar

[13]Opdivo prescribing information. Last accessed December 13 2015 from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125527s000lbl.pdfOpdivo prescribing informationLast accessed December 13 2015 fromhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125527s000lbl.pdfSearch in Google Scholar

[14]Opdivo prescribing information. Last accessed January 2 2016 from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001 876.jsp&mid=WC0b01ac058001d124Opdivo prescribing informationLast accessed January 2 2016 fromhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001 876.jsp&mid=WC0b01ac058001d124Search in Google Scholar

[15]Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33(18):2004-12.GettingerSNHornLGandhiLSpigelDRAntoniaSJRizviNAet alOverall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerJ Clin Oncol2015331820041210.1200/JCO.2014.58.3708Search in Google Scholar

[16]Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-65.RizviNAMazièresJPlanchardDStinchcombeTEDyGKAntoniaSJet alActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncol20151632576510.1016/S1470-2045(15)70054-9Search in Google Scholar

[17]Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35.BrahmerJReckampKLBaasPCrinòLEberhardtWEPoddubskayaEet alNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerN Engl J Med201537321233510.1056/NEJMoa1504627468140026028407Search in Google Scholar

[18]Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627-39.BorghaeiHPaz-AresLHornLSpigelDRSteinsMReadyNEet alNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerN Engl J Med20153731716273910.1056/NEJMoa1507643570593626412456Search in Google Scholar

[19]Horn L, Brahmer J, Reck M, Borghaei H, Spigel D, Steins M et al. Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous non-small cell lung cancer: Subgroup analyses and patient reported outcomes. Ann Oncol 2015;26:ix125HornLBrahmerJReckMBorghaeiHSpigelDSteinsMet alPhase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous non-small cell lung cancer: Subgroup analyses and patient reported outcomesAnn Oncol201526ix12510.1093/annonc/mdv532.01Search in Google Scholar

[20]Gettinger S, Shepherd F, Antonia S, Brahmer J, Chow L, Juergens R et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol. 2014;32:abstr 8024GettingerSShepherdFAntoniaSBrahmerJChowLJuergensRet alFirst-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 statusJ Clin Oncol201432abstr 802410.1200/jco.2014.32.15_suppl.8024Search in Google Scholar

[21]Antonia S, Brahmer J, Gettinger S, Chow L, Juergens R, Shepherd F et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (Pt-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32:abstr 8113AntoniaSBrahmerJGettingerSChowLJuergensRShepherdFet alNivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (Pt-DC) in advanced non-small cell lung cancer (NSCLC)J Clin Oncol201432abstr 811310.1200/jco.2014.32.15_suppl.8113Search in Google Scholar

[22]Rizvi N, Gettinger S, Goldman J, Hellmann M, Chow L, Juergens R et al. Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC). WCLC 2015 September 6-9 2015, ORAL02.05RizviNGettingerSGoldmanJHellmannMChowLJuergensRet alSafety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)WCLC 2015 September 6-9 2015, ORAL02.05Search in Google Scholar

[23]Rizvi N, Chow L, Borghaei H, Shen Y, Harbison C, Alaparthy S et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR Mt) advanced NSCLC. J Clin Oncol. 2014;32:abstr 8022.RizviNChowLBorghaeiHShenYHarbisonCAlaparthySet alSafety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR Mt) advanced NSCLCJ Clin Oncol201432abstr 802210.1200/jco.2014.32.15_suppl.8022Search in Google Scholar

[24]Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34.LarkinJChiarion-SileniVGonzalezRGrobJJCoweyCLLaoCDet alCombined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaN Engl J Med20153731233410.1056/NEJMoa1504030Search in Google Scholar

[25]Keytruda prescribing information. Last accessed December 13 2015 from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s005lbl.pdfKeytruda prescribing informationLast accessed December 13 2015 fromhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s005lbl.pdfSearch in Google Scholar

[26]Keytruda prescribing information. Last accessed December 13 2015 from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp&mid=WC0b01ac058001d124Keytruda prescribing informationLast accessed December 13 2015 fromhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp&mid=WC0b01ac058001d124Search in Google Scholar

[27]Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.GaronEBRizviNAHuiRLeighlNBalmanoukianASEderJPet alPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med20153722120182810.1056/NEJMoa1501824Search in Google Scholar

[28]Hellmann M, Garon E, Gandhi L, Hui R, Zhang J, Rangwala R et al. Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced NSCLC. WCLC 2015 September 6-9 2015, MINI03.05HellmannMGaronEGandhiLHuiRZhangJRangwalaRet alEfficacy of Pembrolizumab in Key Subgroups of Patients with Advanced NSCLCWCLC 2015 September 6-9 2015, MINI03.05Search in Google Scholar

[29]Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015 Dec 18; [Epub ahead of print]HerbstRSBaasPKimDWFelipEPérez-GraciaJLHanJYet alPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2015Dec18[Epub ahead of print]10.1016/S0140-6736(15)01281-7Search in Google Scholar

[30]Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419-25.SperdutoPWKasedNRobergeDXuZShanleyRLuoXet alSummary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastasesJ Clin Oncol20123044192510.1200/JCO.2011.38.0527Search in Google Scholar

[31]Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, Moore B et al. Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). J Clin Oncol. 2015;33:abstr 8005.MulvennaPNankivellMBartonRFaivre-FinnCWilsonPMooreBet alWhole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061)J Clin Oncol201533abstr 800510.1200/jco.2015.33.15_suppl.8005Search in Google Scholar

[32]Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris J et al. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol. 2015;33:abstr 8035.GoldbergSGettingerSMahajanAHerbstRChiangATsiourisJet alActivity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastasesJ Clin Oncol201533abstr 803510.1200/jco.2015.33.15_suppl.8035Search in Google Scholar

[33]Besse B, Johnson M, Janne P, Garassino M, Eberhardt W, Peters S et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). ECC 2015 September 25-29 2015, LBA 16BesseBJohnsonMJannePGarassinoMEberhardtWPetersSet alPhase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)ECC 2015 September 25-29 2015, LBA 1610.1016/S0959-8049(16)31938-4Search in Google Scholar

[34]Vansteenkiste J, Fehrenbacher L, Spira A, Mazieres J, Park K, Smith D et al. Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). ECC 2015 September 25-29 2015, LBA 14VansteenkisteJFehrenbacherLSpiraAMazieresJParkKSmithDet alAtezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)ECC 2015 September 25-29 2015, LBA 1410.1016/S0959-8049(15)30072-1Search in Google Scholar

[35]Camidge R, Liu S, Powderly J, Ready N, Hodi S, Gettinger S et al. Atezolizumab (MPDL3280A) Combined with Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): A Phase Ib Safety and Efficacy Update. WCLC 2015 September 6-9 2015, ORAL02.07CamidgeRLiuSPowderlyJReadyNHodiSGettingerSet alAtezolizumab (MPDL3280A) Combined with Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): A Phase Ib Safety and Efficacy UpdateWCLC 2015 September 6-9 2015, ORAL02.07Search in Google Scholar

[36]Rizvi N, Brahmer J, Ou SH, Segal NH, Khleif S, Hwu WJ et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33:abstr 8032.RizviNBrahmerJOuSHSegalNHKhleifSHwuWJet alSafety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)J Clin Oncol201533abstr 803210.1200/jco.2015.33.15_suppl.8032Search in Google Scholar

[37]Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.BrahmerJRTykodiSSChowLQHwuWJTopalianSLHwuPet alSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med20123662624556510.1056/NEJMoa1200694356326322658128Search in Google Scholar

[38]Rizvi N, Chaft J, Balmanoukian A, Goldberg S, Sanborn R, Steele K et al. Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. J Immunother Cancer. 2015;3:P193.RizviNChaftJBalmanoukianAGoldbergSSanbornRSteeleKet alTumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 statusJ Immunother Cancer20153P19310.1186/2051-1426-3-S2-P193Search in Google Scholar

[39]Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847-56.PatelSPKurzrockR.PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMol Cancer Ther20151448475610.1158/1535-7163.MCT-14-0983Search in Google Scholar

[40]Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.LeDTUramJNWangHBartlettBRKemberlingHEyringADet alPD-1 Blockade in Tumors with Mismatch-Repair DeficiencyN Engl J Med20153722625092010.1056/NEJMoa1500596Search in Google Scholar

[41]Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187-99.BradleyJDPaulusRKomakiRMastersGBlumenscheinGSchildSet alStandard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 studyLancet Oncol20151621879910.1016/S1470-2045(14)71207-0Search in Google Scholar

[42]Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25(13):1698-704.VokesEEHerndonJE2ndKelleyMJCicchettiMGRamnathNNeillHet alInduction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group BJ Clin Oncol20072513169870410.1200/JCO.2006.07.356917404369Search in Google Scholar

[43]Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol. 2012;23(7):1730-8.JalalSIRiggsHDMelnykARichardsDAgarwalaANeubauerMet alUpdated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US OncologyAnn Oncol20122371730810.1093/annonc/mdr56522156624Search in Google Scholar

[44]Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-6.AhnJSAhnYCKimJHLeeCGChoEKLeeKCet alMultinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04J Clin Oncol201533242660610.1200/JCO.2014.60.013026150444Search in Google Scholar

[45]Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-31.PostowMACallahanMKBarkerCAYamadaYYuanJKitanoSet alImmunologic correlates of the abscopal effect in a patient with melanomaN Engl J Med2012366109253110.1056/NEJMoa1112824334520622397654Search in Google Scholar

[46]Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712-20.GibneyGTKudchadkarRRDeContiRCThebeauMSCzuprynMPTettehLet alSafety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanomaClin Cancer Res20152147122010.1158/1078-0432.CCR-14-2468462068425524312Search in Google Scholar

[47]Stewart TJ, Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol. 2007;179(5):2851-9.StewartTJAbramsSI.Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growthJ Immunol200717952851910.4049/jimmunol.179.5.285117709499Search in Google Scholar

[48]Carrizosa DR, Gold KA. New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(5):553-9.CarrizosaDRGoldKA.New strategies in immunotherapy for non-small cell lung cancerTransl Lung Cancer Res2015455539Search in Google Scholar

[49]Agra Y, Pelayo M, Sacristan M, Sacristán A, Serra C, Bonfill X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev. 2003;(4):CD001990.AgraYPelayoMSacristanMSacristánASerraCBonfillX.Chemotherapy versus best supportive care for extensive small cell lung cancerCochrane Database Syst Rev20034CD001990Search in Google Scholar

[50]Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20(24):4665-72.SundstrømSBremnesRMKaasaSAasebøUHatlevollRDahleRet alCisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-upJ Clin Oncol2002202446657210.1200/JCO.2002.12.111Search in Google Scholar

[51]O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441-7.O’BrienMECiuleanuTETsekovHShparykYCuceviâBJuhaszGet alPhase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancerJ Clin Oncol200624345441710.1200/JCO.2006.06.5821Search in Google Scholar

[52]von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658-67.von PawelJSchillerJHShepherdFAFieldsSZKleisbauerJPChryssonNGet alTopotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancerJ Clin Oncol19991726586710.1200/JCO.1999.17.2.658Search in Google Scholar

[53]Antonia S, Bendell J, Taylor MH, Calvo E, Jaeger D, De Braud F et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol. 2015;33:abstr 7503.AntoniaSBendellJTaylorMHCalvoEJaegerDDe BraudFet alPhase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032J Clin Oncol201533abstr 750310.1200/jco.2015.33.15_suppl.7503Search in Google Scholar

[54]Ott PA, Fernandez ME, Hiret S, Kim DW, Moss RA, Winser T et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol. 2015;33:abstr 7502.OttPAFernandezMEHiretSKimDWMossRAWinserTet alPembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028J Clin Oncol201533abstr 750210.1200/jco.2015.33.15_suppl.7502Search in Google Scholar

[55]Kennedy BJ. The snail’s pace of lung carcinoma chemotherapy. Cancer. 1998;82(5):801-3.KennedyBJ.The snail’s pace of lung carcinoma chemotherapyCancer1998825801310.1002/(SICI)1097-0142(19980301)82:5<801::AID-CNCR1>3.0.CO;2-MSearch in Google Scholar